Human trophoblast stem cells (hTSC) for research

Accelerated Biosciences focuses on leveraging human trophoblast stem cells (hTSCs) to advance regenerative medicine. The hTSC platform is notable for its ethical sourcing and unique properties, including immune privilege, genetic stability, and exceptional expansion capacity. These characteristics enable hTSCs to perform functions akin to various cell types, making them a promising starting material for developing therapeutic products. The company offers a range of hTSC-derived cell lines and exosomes, which are recognized as optimal for regenerative applications due to their ability to express numerous genetic markers and their GMP-eligible status.

In addition to the hTSC platform, Accelerated Biosciences has developed genetically engineered platforms (GEMS) that enhance the capabilities of both hTSC and induced pluripotent stem cell (iPSC) technologies. GEMS allows for precise genetic editing, facilitating the creation of complex cell therapies and biopharmaceuticals. The company also provides pre-engineered platforms for antibody production, streamlining the transition from research to commercialization. By offering robust intellectual property protections and support for partners, Accelerated Biosciences aims to reduce development costs and accelerate the delivery of innovative regenerative medicine solutions.

United States

Accelerated Biosciences Corp. is commercializing human trophoblast stem cells isolated from the trophectoderm of embryos from women with ectopic pregnancies. hTSCs are ethically sourced and have immune-privileged characteristics. It is an abundant and dynamic pluripotent stem cell platform for basic research, disease modeling, toxicology, drug discovery, and cell therapy.

Accelerated Biosciences

Company Details